解放军医学院学报Issue(4)：327-328,2.DOI:10.3969/j.issn.2095-5227.2013.04.006
氟维司群治疗受体阳性晚期乳腺癌的疗效观察
Therapeutic effect of fulvestrant on estrogen receptor-positive advanced breast cancer
杨俊兰 1游俊浩 1韩春 1令狐锐霞 1朱艳云 1方平1
作者信息
- 1. 解放军总医院 肿瘤内科，北京 100853
- 折叠
摘要
Abstract
Objective To observe the therapeutic effect and toxicity of fulvestrant on estrogen receptor (ER)-positive advanced breast cancer. Methods Twenty-seven patients who received fulvestrant treatment in our hospital from August 2011 to May 2012 were enrolled in this study. Their clinical data including the disease progression time, overall response rate, clinical beneficial rate, and side effects were analyzed. Results The median disease progression time, objective response rate, and 3-month clinical beneficial rate were 4.8 months, 14.81%(4/27), and 48.15%(13/27), respectively. The main side effects were fatigue and anorexia. Conclusion Fulvestrant is a well-tolerated and effective drug for ER-positive advanced breast cancer when it fails to respond to tamoxifen and aromatase inhibitors.关键词
氟维司群/受体阳性/转移性乳腺癌/内分泌治疗Key words
fulvestrant/receptor positivity/metastatic breast cancer/endpcrine therapy分类
医药卫生引用本文复制引用
杨俊兰,游俊浩,韩春,令狐锐霞,朱艳云,方平..氟维司群治疗受体阳性晚期乳腺癌的疗效观察[J].解放军医学院学报,2013,(4):327-328,2.
